An IPR warning shot for pharma that could resonate far and wide
Earlier this week US hedge fund investor Kyle Bass got the wires buzzing when he reportedly outlined his plans to wage an inter partes review (IPR) war on big pharma at the USPTO’s Patent Trial and Appeal Board (PTAB). According to Bass,…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.